B y the year 2030, pancreatic ductal adenocarcinoma (PDA) will become the second leading cause of cancer-related death in the United States. 1 PDA is often asymptomatic at a curable stage, whereas the majority of patients present with local invasion or metastatic disease. 2 Moreover, adjuvant chemotherapy after resection for PDA offers a proven, albeit limited, overall survival (OS) benefit. [3] [4] [5] To date, 5-fluorouracil (5-FU), gemcitabine (GEM), and their derivatives (eg, capecitabine) are the best available drugs for PDA treatment in the adjuvant setting and represent the current standard of care. 6, 7 Previous studies have explored gene expression transcripts (ie, hENT1, CDA, dCK, RRM1, RRM2) as markers to guide adjuvant therapy. [8] [9] [10] [11] To date there is, however, no standardized predictive biomarker for adjuvant therapy approved for clinical use. Although better, targeted treatment options are in the pipeline, strategies to select resected patients for the optimal adjuvant therapy (ie, GEM vs 5-FU) may provide short-term strategies to favorably improve outcomes.
We have previously evaluated the mRNA binding protein, HuR (ELAVL1), as a predictive marker for PDA response to adjuvant 5-FU and GEM in 3 separate cohorts (Table 1) . [12] [13] [14] HuR is typically located in the nucleus of PDA cells. Under conditions of stress in the tumor microenvironment (eg, hypoxia, glucose deprivation, chemotherapy), HuR translocates from the nucleus to the cytoplasm and binds U-or AU-rich sequences in the 3' untranslated region of select target mRNAs (eg, WEE1, PIM1, TRAIL) important for PDA cell survival and chemotherapy resistance. [15] [16] [17] Generally, this binding stabilizes mRNAs and post-transcriptionally upregulates protein expression. One such identified target is deoxycytidine kinase (dCK), which is critical for DNA synthesis, but is also the ratelimiting GEM metabolizing enzyme. 13 In the laboratory setting, enhanced HuR expression levels and/or cytoplasmic HuR (cHuR) leads to high protein levels of dCK, which can correlate with increased GEM efficacy. 13 Our first 2 studies suggested that increased cHuR expression was a poor overall prognostic marker in a retrospective cohort of patients undergoing resection for PDA. 12, 13 However, in an ad-hoc review of data from a phase III clinical trial by McAllister et al. where patients received multimodality therapy, HuR was not predictive of survival after either adjuvant GEM or 5-FU (Table 1). 14 Based on this previous work, we sought to study HuR in a larger cohort of patients from a 2-armed, multi-institutional, randomized controlled phase III trial. The European Study Group of Pancreatic Cancer (ESPAC)-3 trial was a National Cancer Institute-funded, phase III trial, which randomized patients with resected pancreatic cancer to 1 of 2 approved first-line adjuvant chemotherapies. 18 The results of this trial demonstrated a very limited and nonsignificant difference in median progression-free survival From the (PFS) and OS between 5-FU and GEM (PFS, 14.1 vs 14.3 months, P ¼ 0.53; OS, 23 vs 23.6 months, P ¼ 0.39). Short of a prospective biomarker-driven randomized trial, the present study served as the best cohort of patients available to study HuR as a prognostic and predictive biomarker. The absence of adjuvant radiation in the present study was particularly compelling for this biomarker study, because external beam radiation treatment engages HuR biologically through mechanisms that are independent from those affected by chemotherapy. 19 
METHODS
After study approval from the institutional review board at Thomas Jefferson University, 1233 tissue microarray (TMA) samples were obtained from a total of 379 patients with resected PDA enrolled in the ESPAC-3 trial. In the ESPAC-3 trial, patients were randomly assigned to receive 6 months of either GEM (1000 mg/m 2 intravenous infusion once weekly for 3 of every 4 weeks) (n ¼ 537) or 5-FU þ folinic acid (folinic acid, 20 mg/m 2 intravenous injection þ 5-FU, 425 mg/m 2 intravenous bolus injection given for 5 days every 28 days) (n ¼ 551). 18 The observation arm of this trial was discontinued early due to statistical evidence demonstrating a significant survival benefit in patients receiving adjuvant chemotherapy (n ¼ 61). The 379 patients included in the present study were selected based on the availability of TMA. All available TMA samples were used without additional filtering. All patients received either adjuvant GEM or 5-FU.
Tissue Microarray Preparation
An experienced pathologist evaluated tumor samples from patients enrolled in the ESPAC-3 trial after hematoxylin and eosin staining of sections. TMA samples were generated from a representative area of each tumor with 1 to 8 cores arrayed for each patient. In total, 1233 TMA samples were generated from the 379 patients, 589 from 186 patients who received 5-FU and 644 from 193 patients who received GEM.
Immunohistochemical Analyses
Antigen retrieval was performed using Discovery CCI (Ventana, Tuscon, AZ cat 950-500) for a total application time of 64 minutes. Primary immunolabeling was performed using HuR antibody (3A2) (Santa Cruz Biotechnology, Santa Cruz, CA sc-5261) at a 1:300 dilution with Ventana Antibody Dilution Buffer (cat ADB250) for a 44-minute incubation at room temperature. We have previously published that the HuR antibody is specific for the protein via immunoblotting techniques. 13, 17 Immune complexes were visualized using the ultraView Universal DAB (diaminobenzidine tetrahydrochloride) Detection Kit (Ventana cat 760-500), which uses a rabbit horseradish peroxidase multimer cocktail for secondary immunolabeling. Slides were then washed with a Tris-based reaction buffer (Ventana cat 950-300) and stained with Hematoxylin II (Ventana cat 790-2208) for 8 minutes.
Scoring of the Tissue Microarray
A pathologist (W.J.) with expertise in pancreatic pathology scored cHuR immunolabeling within tumor cells in a blinded manner using a previously published scoring system. 13 The pathologist assessed labeling intensity (strong vs weak), percentage of cell labeling, and cellular localization of labeling (nuclear vs cytoplasmic). Each sample was then graded based on the following scale: 0, no labeling; 1, weak diffuse labeling; 2, strong labeling in less than 50% of tumor cells; 3, strong labeling in greater than 50% of tumor cells. All available cores were graded for each patient. To account for variability in the number of cores, the graded cytoplasmic scores for each patient were averaged to obtain a cHuR score. These were analyzed in dichotomized groups identified as low cHuR (score <1.5) and high cHuR (score !1.5), similar to previously published reports. 13 
Statistical Analyses
All analyses were carried out using SAS version 14.0 (SAS Institute Inc., Cary, NC). Univariate Cox regression was carried out for all control and treatment variables for the response variables of OS time and disease-free survival (DFS) time. Control variables included HuR labeling, age, sex, smoking status, lymph node status, margin status, and clinical stage, whereas treatment variables included 5-FU and GEM. Kaplan-Meier survival curves were used to explore the relation between HuR labeling, treatment, and survival arms. Multivariable Cox regression models were built to investigate associations that appeared in exploratory analysis. These models included HuR labeling levels, treatment, and relevant control variables as covariates. The predictive utility of HuR was evaluated by testing the significance of the interaction between treatment and dichotomized HuR labeling in a Cox proportional hazards regression model. Univariate tests for association of potential confounders with HuR labeling levels were performed using Student t test for normally 
RESULTS

Evaluation of Cytoplasmic HuR Expression and Correlation with Clinicopathologic Features
We received TMAs that included specimens from 379 patients enrolled in the ESPAC-3 trial, of which 186 were treated with 5-FU and 193 with GEM. All samples had at least some trace reactivity to HuR antibody. For patients with more than 1 core sample, the mean variance in cHuR score was 0.228 (AE0.377). Of the 379 patients, 75 (19.8%) had tumors with high cHuR expression and 304 (80.2%) had tumors with low cHuR expression (Fig. 1) . Patient demographics, treatment group allocation, and clinicopathologic features were similar between patients with high and low cHuR expression ( Table 2 ).
Correlation of Cytoplasmic HuR Expression and Response Outcomes
In evaluating the entire cohort, there was no association between cHuR expression and DFS [hazard ratio (HR) ¼ 1. (Table 3) .
Kaplan-Meier survival curves demonstrated a differential response in DFS ( Fig. 2A) when stratified by cHuR expression and treatment arm (P ¼ 0.04). Patients with high cHuR who were treated with 5-FU had a near doubling of median DFS as compared to those treated with GEM (5-FU, 20.1 months, CI: 8.3-36.4 vs GEM 10.9 months, CI: 7.5-14.2, P ¼ 0.012). Median DFS was, however, similar between the treatment arms in patients with low cHuR (5-FU, 12.8 months, CI: 10.6-14.6 vs GEM, 12.9 months, CI: 11.2-15.4, P ¼ 0.44). Overall, the worst DFS was observed in patients with high cHuR who were treated with GEM. A significant differential response was not seen in OS (P ¼ 0.24), although there was a persistent trend toward improved survival in patients with high cHuR who were treated with 5-FU as compared to GEM (5-FU, 27.6 months, CI: 14.2-39.7 vs GEM, 20.7 months, CI: 13.9-26, P ¼ 0.08) (Fig. 2B) .
Unadjusted Cox regression was used to evaluate cHuR as a predictive marker for DFS and OS. This analysis found cHuR to be predictive of DFS when stratified by the treatment arm (P ¼ 0.012) ( Table 4 ). Specifically, high cHuR was associated with improved DFS in patients treated with 5-FU as compared to GEM (HR ¼ 0.51, CI: 0.31-0.85, P ¼ 0.01). In patients treated with GEM, high cHuR was associated with reduced DFS when compared to low cHuR (HR ¼ 1.54, CI: 1.08-2.2, P ¼ 0.02). Overall, cHuR was not a significant predictive marker for OS (P ¼ 0.29). There was a trend toward improved OS in patients with high cHuR treated with 5-FU as opposed to GEM (HR ¼ 0.63, CI: 0.38-1.06, P ¼ 0.08). As seen with DFS, there was again a trend toward reduced DFS with GEM in patients with high cHuR (HR ¼ 1.4, CI: 0.97-1.99, P ¼ 0.07).
Multivariable Cox regression was performed, adjusting cHuR expression for lymph node status and resection margins (Table 5) . 
DISCUSSION
The search for a robust reproducible predictive biomarker for pancreatic cancer has eluded investigators for decades. In a previous study of 40 resected PDA specimens from our group, low cHuR correlated with a 7-fold increased risk in mortality in patients receiving adjuvant GEM therapy (HR ¼ 7.34, CI: 2.05-26.22, P ¼ 0.0022). 13 These findings were later supported in a smaller cohort from the same institution. 12 In a group of 24 patients who received adjuvant GEM monotherapy, low cHuR was predictive of worse OS as compared to high cHuR (HR ¼ 2.84, CI: 1.04-7.74, P ¼ 0.04). These results were attributed to the role of HuR in upregulating and activating dCK, an enzyme responsible for metabolizing GEM to its active metabolites. 13 These data were validated by in vitro experiments, and supported a model in which HuR sensitized tumor cells to the action of GEM by enhancing the prodrug's conversion to its active form. 13 Recently, McAllister et al 14 assessed the predictive value of cHuR in 165 patients from the Radiation Therapy Oncology Group (RTOG) 9704 trial. Although the present study had the advantage of including a large sample of patients from a randomized trial, radiation therapy administration was interpreted as a confounder. 20 Ionizing radiation complicates HuR biology by inducing phosphorylation of HuR by checkpoint kinase 2, which causes dissociation of HuR-mRNA complexes, altered downstream gene expression, and improved cell survival in vitro. 19 In the RTOG 9704 cohort, there was no difference between low and high HuR expressing tumors with respect to DFS or OS in either arm. It was presumed that the radiation effect might have contributed to the lack of any interaction between cHuR and outcome.
Since the publication of these studies, we and others have, however, demonstrated through in vivo and in vitro models that HuR actually supports a therapeutic resistant phenotype in PDA through HuR-mediated overexpression of key prosurvival proteins. [21] [22] [23] [24] Most recently, Elebro et al 24 reported an association between high cHuR expression and reduced OS in GEM-treated patients with pancreatobiliary-type periampullary tumors compared with untreated controls (HR 2.07, 95% CI: 1.03-4.17, P ¼ 0.028). These later studies conflict with the earlier work, and indicate that HuR status is more likely to promote resistance to treatment than it is to enhance drug sensitivity. For this reason, we specifically sought to analyze a cohort of samples from a rigorously accrued phase III trial with robust patient follow-up and no radiation therapy arm.
Herein, we evaluated TMA samples generated from tumors of patients enrolled in the ESPAC-3 phase III trial in which patients received either GEM or 5-FU monotherapy, without any radiation. cHuR was evaluated objectively as a prognostic marker and as predictive marker for each specific treatment. cHuR expression alone was not an informative prognostic marker for DFS or OS in the total cohort. In the 20% of our cohort with high cHuR expression, a significant survival advantage was, however, seen in patients receiving 5-FU, whereas these patients' tumors were relatively resistant to GEM. This translated to a near doubling in median DFS (20.1 vs 10.9 months, P ¼ 0.04). Notably, these values were above and below the median DFS for the entire ESPAC-3 cohort, (14.3 months). 7 Patients with low cHuR had no difference in median DFS with respect to treatment arm, and the values approximated the abovementioned median value for the ESPAC-3 trial. This observation provides a measure of validation for the present study, because the subgroup with low cHuR comprised the majority of the current cohort (80.2%, n ¼ 304). 18 Once adjusted for lymph nodes status and positive resection margins, cHuR was no longer a significant predictive marker. There, however, remained a trend toward improved DFS with 5-FU treatment in patients with high cHuR. The loss of statistical significance is most likely due to the small sample size of patients with high cHuR (19.8%, n ¼ 75) relative to the overall large cohort studied.
GEM and 5-FU (including capecitabine, a prodrug of 5-FU) therapy have remained the standard of care for PDA treatment in the adjuvant setting based on the results of ESPAC-3, and other phase III clinical trials. [3] [4] [5] 18, 20, 25 Results from the Charité Onkologie-001 trial demonstrated a significant improvement in both DFS and OS in patients with PDA who received adjuvant GEM versus observation (DFS, 13.4 vs 6.7 months, P < 0.001; OS, 22.8 vs 20.2 months, P ¼ 0.01). 4, 5 Soon after, the RTOG9704 trial randomized patients to receive 5-FU-based chemoradiation sandwiched between GEM or 18 Recently reported, ESPAC-4 found a small benefit in median survival with combination GEM/capecitabine (a 5-FU derivative) compared with GEM alone (28 vs 25.5 months, P ¼ 0.032). 7 Additional GEM and 5-FU based multiagent regimens are currently being tested in phase II and III trials, providing alternative treatment strategies (NCT02243007, NCT01964430). Thus, there remains an opportunity to better select patients for specific regimens, to optimize treatment efficacy and minimize treatment toxicity.
Compared to our previous studies, we strongly believe this current cohort represents the best population available to study in the adjuvant setting, because all patients were enrolled in a randomized trial with long-term follow-up and no radiation confounder. We acknowledge limitations of our analysis. One limitation is that our analysis remains underpowered to detect a true difference in survival with respect to HuR status. In this cohort, only 19.8% of patients had tumors with high cHuR expression. Underscoring this point, detecting high cHuR in less than 20% of patients from ESPAC-3 does not correlate with previous scoring patterns in which high cHuR was detected in closer to half the tumors evaluated in the study. [12] [13] [14] Another limitation of using HuR as a biomarker is the reliance on immunohistochemistry and a subjective scoring system. Scoring is dependent on a trained pathologist and may be subject to variable interpretation by different pathologists. The present study only 21, 22 Perhaps HuR regulates specific transcripts that contribute to 5-FU sensitivity. Alternatively, high cHuR may be a marker of rapid cell division, and these cells may be particularly susceptible to 5-FU cytotoxic therapy. 14 Regardless of the exact mechanism, there is an opportunity to optimize outcomes using the drugs that we currently have available, and offer an opportunity to personalize treatments for patients with PDA. As a next step, patients enrolled in the Adjuvant Pancreatic Adenocarcinoma Clinical Trial and ESPAC-4 trial would be the preferred cohorts to test the predictive value of cHuR in the context of relevant combination therapies, which are already 5-FU and GEM based, and provide a basis for a prospective, personalized trial in which treatments are based on cHuR expression.
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